Furthermore, the median overall survival (OS) in metastatic TNBC (mTNBC) is around 18 months, whereas in the luminal breast cancer cases, expressing ER/PR or HER2, it exceed 5 years. This evidence concerns the gene ERBB2 and breast carcinoma.